These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36786145)

  • 21. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.
    Lu MD; Li H; Nie JH; Li S; Ye HS; Li TT; Wu ML; Liu J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
    Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
    Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
    Kurupi R; Floros KV; Jacob S; Chawla AT; Cai J; Hu B; Puchalapalli M; Coon CM; Khatri R; Crowther GS; Egan RK; Murchie E; Greninger P; Dalton KM; Ghotra MS; Boikos SA; Koblinski JE; Harada H; Sun Y; Morgan IM; Basu D; Dozmorov MG; Benes CH; Faber AC
    Cancer Res Commun; 2022 Sep; 2(9):1061-1074. PubMed ID: 36506869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
    Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
    Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
    Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan.
    Chang CF; Yang MH; Lee JH; Shih SR; Lin CH; Chen CP; Wu CE; Lu JY
    Am J Cancer Res; 2022; 12(11):5342-5350. PubMed ID: 36504909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
    Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
    Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.
    Zhao M; Guo W; Wu Y; Yang C; Zhong L; Deng G; Zhu Y; Liu W; Gu Y; Lu Y; Kong L; Meng X; Xu Q; Sun Y
    Acta Pharm Sin B; 2019 Mar; 9(2):304-315. PubMed ID: 30972278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
    Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
    Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
    Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
    J Clin Endocrinol Metab; 2009 Oct; 94(10):4107-12. PubMed ID: 19723757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy.
    Kulkarni P; Hall J; Wang L; Henderson S
    Cureus; 2021 Dec; 13(12):e20693. PubMed ID: 35106230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
    Lu H; Liu C; Huynh H; Le TBU; LaMarche MJ; Mohseni M; Engelman JA; Hammerman PS; Caponigro G; Hao HX
    Oncotarget; 2020 Jan; 11(3):265-281. PubMed ID: 32076487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.